Development and internal validation of a predictive model of overall and progression-free survival in eribulin-treated patients with breast cancer based on baseline peripheral blood parameters
Nomograms incorporating peripheral blood parameters may improve the accuracy of predicting OS and PFS in patients treated with eribulin. Our prediction model may help decision-making for breast cancer patients who are considering eribulin treatment.
Authors
- Masataka Igeta (ORCID: https://orcid.org/0000-0001-8706-4231)
- Masayuki Nagahashi (ORCID: https://orcid.org/0000-0002-9308-448X)
- Takashi Daimon (ORCID: https://orcid.org/0000-0001-8930-8762)
- Yasuo Miyoshi (ORCID: https://orcid.org/0000-0001-8535-4008)
- Keiko Natori (ORCID: https://orcid.org/0000-0001-8401-9769)
- Sadako Akashi‐Tanaka (ORCID: https://orcid.org/0000-0002-2065-7742)
- Takashi Morimoto (ORCID: https://orcid.org/0000-0003-3880-3362)
Institutions
- Hyogo Medical University (JP)
- Tokyo Women's Medical University (JP)
- Hyogo University (JP)
Publication Details
- Journal
- Breast Cancer
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1007/s12282-025-01678-7
- Citations
- 3
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Hyogo College of Medicine